Abughanimeh Omar K, Baljevic Muhamed, Nester Alex
Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, USA.
Division of Hematology-Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, USA.
Cureus. 2024 Jan 20;16(1):e52633. doi: 10.7759/cureus.52633. eCollection 2024 Jan.
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA), which copresents with microangiopathic hemolytic anemia, thrombocytopenia, and kidney injury. While typical HUS is normally preceded by infections such as Shiga-toxin-producing atypical HUS (aHUS) has a genetic component that leads to dysregulation of the alternative complement pathway. We report a case of a 69-year-old female who developed aHUS after undergoing an elective knee surgery. Genetic testing revealed novel mutations affecting diacylglycerol kinase epsilon (DGKE) protein and complement factor I (CFI) that were not reported before as pathogenic. The patient was treated with eculizumab, leading to the complete resolution of TMA with no lasting organ damage.
溶血性尿毒症综合征(HUS)是一种血栓性微血管病(TMA),其临床表现为微血管病性溶血性贫血、血小板减少和肾损伤。典型的HUS通常在诸如产志贺毒素的感染之后出现,而非典型HUS(aHUS)则有一个导致替代补体途径失调的遗传成分。我们报告一例69岁女性患者,该患者在接受择期膝关节手术后发生了aHUS。基因检测发现了影响二酰基甘油激酶ε(DGKE)蛋白和补体因子I(CFI)的新突变,这些突变以前未被报告为致病性突变。该患者接受了依库珠单抗治疗,导致TMA完全缓解,且无持久的器官损伤。